Cargando…

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?

Detalles Bibliográficos
Autores principales:	Van Baelen, Karen, Desmedt, Christine, Wildiers, Hans, Neven, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113101/ https://www.ncbi.nlm.nih.gov/pubmed/37082695 http://dx.doi.org/10.21037/atm-23-41

Ejemplares similares

Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors
por: Lambrechts, Yentl, et al.
Publicado: (2023)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy
por: Hatse, Sigrid, et al.
Publicado: (2022)

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
por: Dong, Brian, et al.
Publicado: (2023)

Broadening our perspectives on ICU delirium risk factors
por: Skrobik, Yoanna
Publicado: (2009)

Passing the microphone: broadening perspectives by amplifying underrepresented voices
por: Wondimagegn, Dawit, et al.
Publicado: (2020)

Is CDK9 a promising target for both primary and metastatic osteosarcoma?
por: Qin, Jiang-Jiang
Publicado: (2019)

How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research
por: Pate, Leigh, et al.
Publicado: (2021)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Can we be SMaRT-er in our approach to cancer therapy?
por: Gruber, Christina, et al.
Publicado: (2015)

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
por: Adams, E., et al.
Publicado: (2021)

Broadening Participation in the Life Sciences: Current Landscape and Future Directions
por: Gibbs, Kenneth D., et al.
Publicado: (2016)

Broadening Our Understanding Type 1 Diabetes Heterogeneity by Exploring Effects of Race/Ethnicity on Disease Trajectory
por: Hessner, Martin J, et al.
Publicado: (2020)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016)

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer
por: Lambrechts, Yentl, et al.
Publicado: (2023)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Therapeutic potential of CDK11 in cancer
por: Blazek, Dalibor
Publicado: (2023)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
por: Wang, Ping, et al.
Publicado: (2023)

(Re)contextualizing the Trauma to Prevent or Treat PTSD-Related Hypermnesia
por: Desmedt, Aline
Publicado: (2021)

International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
por: Pagani, Olivia, et al.
Publicado: (2010)

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
por: Munzone, E., et al.
Publicado: (2021)

Update on triple-negative breast cancer: prognosis and management strategies
por: Brouckaert, Olivier, et al.
Publicado: (2012)

Spectral line broadening by plasmas
por: Griem, Hans
Publicado: (2012)

A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer
por: Mckertish, Candice Maria, et al.
Publicado: (2023)

Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer
por: Izci, Hava, et al.
Publicado: (2022)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor
por: Nerad, Elias, et al.
Publicado: (2019)

Oxygen-independent, CDK4/CDK6-dependent degradation of hypoxia-inducible factor-1α takes cancers’ breath away
por: Neckers, Len
Publicado: (2022)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
por: Tang, Hiu, et al.
Publicado: (2023)

Broadening the Genetic Horizons of CADASIL: New Variants of the NOTCH3 Gene Revealed and their Association with CADASIL
por: Mishra, Biswamohan, et al.
Publicado: (2023)

The role of CDK in the initiation step of DNA replication in eukaryotes
por: Tanaka, Seiji, et al.
Publicado: (2007)

CDK8 as the STAT1 serine 727 kinase?
por: Staab, Julia, et al.
Publicado: (2013)

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
por: Nguyen, Toan D., et al.
Publicado: (2023)

Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?
por: Winters-Stone, Kerri M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_61k4nqsr4am2ljh3hacftr4bhv